See more : Topower Co., Ltd. (3226.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Telix Pharmaceuticals Limited (TLPPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Telix Pharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Advanced Info Service Public Company Limited (AVIVF) Income Statement Analysis – Financial Results
- Hypothekarbank Lenzburg AG (HBLN.SW) Income Statement Analysis – Financial Results
- Antony Waste Handling Cell Limited (AWHCL.BO) Income Statement Analysis – Financial Results
- Hello Pal International Inc. (HP.CN) Income Statement Analysis – Financial Results
- Gores Guggenheim, Inc. (GGPIU) Income Statement Analysis – Financial Results
Telix Pharmaceuticals Limited (TLPPF)
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 496.66M | 160.10M | 7.60M | 5.21M | 3.49M | 195.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 188.16M | 130.76M | 37.36M | 22.09M | 15.36M | 0.00 | 3.79K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 308.50M | 29.34M | -29.77M | -16.88M | -11.88M | 195.14K | -3.79K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 62.12% | 18.32% | -391.85% | -323.75% | -340.75% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 128.84M | 57.86M | 34.14M | 23.09M | 21.16M | 18.69M | 2.98M | 10.00K | 62.00K | 0.00 | 0.00 |
| General & Administrative | 78.99M | 77.32M | 34.92M | 7.71M | 6.51M | 8.50M | 2.46M | 20.00K | 54.00K | 0.00 | 0.00 |
| Selling & Marketing | 54.87M | 16.19M | 5.89M | 1.20M | 312.00K | 577.95K | 213.77K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.85M | 44.66M | 17.35M | 9.29M | 7.22M | 9.08M | 2.67M | 20.00K | 54.00K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 3.09M | 23.55M | 2.96M | 11.44M | 11.63M | 112.64K | 0.00 | 0.00 | -994.00K | -578.00K |
| Operating Expenses | 308.50M | 102.52M | 51.48M | 32.38M | 28.38M | 27.85M | 6.52M | 30.00K | 116.00K | -994.00K | -578.00K |
| Cost & Expenses | 451.03M | 233.28M | 88.84M | 54.47M | 43.74M | 27.85M | 6.52M | 30.00K | 116.00K | -994.00K | -578.00K |
| Interest Income | 235.00K | 1.00K | 163.00K | 67.00K | 98.00K | 332.75K | 38.98K | 14.00K | 16.00K | 0.00 | 0.00 |
| Interest Expense | 13.14M | 406.00K | 189.00K | 1.18M | 2.41M | 29.02K | 9.40K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.74M | 5.38M | 5.17M | 4.88M | 4.24M | 6.93K | 3.79K | 30.00K | 116.00K | 0.00 | 0.00 |
| EBITDA | 22.97M | -92.84M | -70.07M | -44.94M | -36.17M | -25.82M | -6.77M | -14.00K | -16.00K | -994.00K | -578.00K |
| EBITDA Ratio | 4.62% | -42.35% | -1,001.49% | -851.16% | -1,033.57% | -8,034.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 51.89M | -73.18M | -81.25M | -49.25M | -40.26M | -15.68M | -6.37M | -30.00K | -116.00K | -994.00K | -578.00K |
| Operating Income Ratio | 10.45% | -45.71% | -1,069.60% | -944.81% | -1,155.12% | -8,037.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -48.80M | -24.52M | -17.79M | -11.00M | 9.13M | 11.94M | 142.22K | -14.00K | -16.00K | 0.00 | 0.00 |
| Income Before Tax | 3.09M | -98.62M | -99.04M | -60.25M | -42.82M | -15.71M | -6.38M | -44.00K | -132.00K | -497.00K | -289.00K |
| Income Before Tax Ratio | 0.62% | -61.60% | -1,303.83% | -1,155.82% | -1,228.55% | -8,052.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.12M | 5.46M | -18.53M | -15.37M | -14.95M | -1.88M | 9.40K | -14.00K | -16.00K | -497.00K | -289.00K |
| Net Income | 5.21M | -104.08M | -80.51M | -44.89M | -27.87M | -13.83M | -6.38M | -44.00K | -132.00K | -497.00K | -289.00K |
| Net Income Ratio | 1.05% | -65.01% | -1,059.90% | -861.06% | -799.63% | -7,087.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | -0.07 | -0.05 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | -0.07 | -0.05 | 0.00 | 0.00 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 323.66M | 310.64M | 282.21M | 257.27M | 233.44M | 202.12M | 127.99M | 0.00 | 0.00 | 38.67M | 38.67M |
| Weighted Avg Shares Out (Dil) | 323.71M | 310.64M | 282.21M | 257.27M | 233.44M | 202.12M | 127.99M | 0.00 | 0.00 | 38.67M | 38.67M |
Focus on supply chain and manufacturing in expansion plans: Telix Pharma CEO
Telix Pharmaceuticals Limited (TLPPF) Q2 2024 Earnings Call Transcript
Australia's Telix Pharma to raise $398 mln in debt to fund cancer therapy
Telix Pharma Stock: Prostate Cancer Treatments Could Lead To Increased Value
Telix Announces Launch of Proposed Initial Public Offering in the United States
Revenue Stage Telix Pharmaceuticals Seeks $100 Million U.S. IPO
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
Telix Pharmaceuticals Limited (TLPPF) Q4 2023 Earnings Call Transcript
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
Source: https://incomestatements.info
Category: Stock Reports